Compass Therapeutics (CMPX) Operating Leases (2021 - 2026)

Compass Therapeutics has reported Operating Leases for 6 years, with the latest figure at $8.4 million in Q1 2026.

• Quarterly Operating Leases rose 34.22% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (up 34.22% YoY) and the FY2025 annual result came in at $8.8 million, up 40.23% from the prior year.
• Operating Leases retreated to $8.4 million in Q1 2026 per CMPX's latest filing, from $8.8 million in the prior quarter.
• Over five years, Operating Leases peaked at $9.8 million in Q3 2025 and troughed at $536000.0 in Q4 2023.
• A 5-year average of $4.7 million and a median of $3.0 million in 2022 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2024: Operating Leases sank 70.84% in 2023, then surged 1074.63% in 2024.
• Over 5 years, Operating Leases stood at $1.8 million in 2022, then sank by 70.84% to $536000.0 in 2023, then soared by 1074.63% to $6.3 million in 2024, then jumped by 40.23% to $8.8 million in 2025, then slipped by 4.66% to $8.4 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $8.4 million, $8.8 million, and $9.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.